title: Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients.
abstract: OBJECTIVE
  To investigate the incidence of iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients by a prospective and observer-masked study.
  
  
  METHODS
  Sixty-nine eyes of 69 glaucoma patients were included. Patients who had undergone intraocular surgery, laser trabeculoplasty, and laser iridotomy within 12 months before enrollment, and patients with history of uveitis and any changes in antiglaucoma drugs within 6 months before enrollment were excluded. Iridial photographs were taken by one examiner under the same conditions at 1, 3, and 6 months after the initiation of latanoprost treatment. Three glaucoma specialists, masked of patient information, independently assessed the iridial pigmentation. Cases with iridial pigmentation diagnosed by three specialists were categorized as showing a definite increase in iridial pigmentation.
  
  
  RESULTS
  A definite increase in iridial pigmentation occurred in 3.5%, 9.7%, and 35.0% of eyes within 1, 3, and 6 months of treatment, respectively. Age, gender, or concomitantly used eyedrops did not significantly influence the incidence of iridial pigmentation within 6 months of instillation. A reduction of intraocular pressure by latanoprost did not differ significantly between patients with and without iridial pigmentation.
  
  
  CONCLUSIONS
  The incidence of iridial pigmentation by latanoprost ophthalmic solution in Japanese patients was higher than previously reported values in pigmented races.
authors.affiliation: Department of Ophthalmology, Yamanashi Medical University, Tamaho, Yamanashi, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Chiba
authors.forename: K
authors.initials: K
authors.lastname: Kashiwagi
authors.forename: S
authors.initials: S
authors.lastname: Kogure
authors.forename: K
authors.initials: K
authors.lastname: Abe
authors.forename: T
authors.initials: T
authors.lastname: Shibuya
authors.forename: M
authors.initials: M
authors.lastname: Furuichi
authors.forename: H
authors.initials: H
authors.lastname: Iijima
authors.forename: S
authors.initials: S
authors.lastname: Tsukahara
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005127:Eye Color; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D007429:Intraocular Pressure / Q000187:drug effects; D007498:Iris / Q000187:drug effects*; D007499:Iris Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D007564:Japan / Q000453:epidemiology; D000077338:Latanoprost; D008297:Male; D008548:Melanosis / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost